UK Markets open in 2 hrs 30 mins

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
339.26-2.09 (-0.61%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 581.94B
Enterprise value 388.73B
Trailing P/E N/A
Forward P/E 17.66
PEG ratio (5-yr expected) 1-0.22
Price/sales (ttm)10.55
Price/book (mrq)N/A
Enterprise value/revenue 311.42
Enterprise value/EBITDA 715.91

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3464.00
52-week low 358.81
50-day moving average 3360.99
200-day moving average 3231.08

Share statistics

Avg vol (3-month) 34.17M
Avg vol (10-day) 33.91M
Shares outstanding 5241.52M
Implied shares outstanding 6N/A
Float 77.48M
% held by insiders 11.18%
% held by institutions 116.70%
Shares short (29 Jul 2021) 41.56M
Short ratio (29 Jul 2021) 40.48
Short % of float (29 Jul 2021) 4N/A
Short % of shares outstanding (29 Jul 2021) 40.64%
Shares short (prior month 29 Jun 2021) 42.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 52.41%
Operating margin (ttm)71.20%

Management effectiveness

Return on assets (ttm)68.31%
Return on equity (ttm)133.85%

Income statement

Revenue (ttm)7.77B
Revenue per share (ttm)31.98
Quarterly revenue growth (yoy)12,630.20%
Gross profit (ttm)-222.04M
EBITDA 5.58B
Net income avi to common (ttm)4.07B
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)914.9M
Total cash per share (mrq)3.75
Total debt (mrq)256.8M
Total debt/equity (mrq)4.68
Current ratio (mrq)2.67
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-354.87M
Levered free cash flow (ttm)-1.08B